QuickView for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=C6EEB24438E91236A278BAA17D0F98DE;jsessionid=4E424E1535B964284C2AF9C387DA16C3;jsessionid=488CBD111883FD29309C48C3F67E3ED2;jsessionid=6BA0878CC96DB080B124A8A3304A3FB1;jsessionid=21B9763974C3FDC50FB2633B16499D1E;jsessionid=FA881359FEC92A550637831A469F2212;jsessionid=437262EB9AC2F39707B37A3517899648 (gene)

1. Cyst fluid glycoproteins accurately distinguishing malignancies of pancreatic cystic neoplasm.
2. Clinical Evaluation of Cystic Renal Masses With Bosniak Classification by Contrast-Enhanced Ultrasou…
3. Feasibility of Surveillance for Mucinous Cystic Neoplasm of the Pancreas: A Multi-Institutional Retr…
4. Clinicopathological and genetic characteristics of congenital cystic adenomatoid malformation of lun…
5. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal mas…

There were no clinical trials for YDL103C;jsessionid=15F15BB478DC6C77651BC16CE76A6F8A;jsessionid=FA09DD4A5D65571BA1AD979499E356E2;jsessionid=5DB5107377C50D220B2B02849FAC3A0E;jsessionid=161EA4FB6A70DC430F4519468CC7F620;jsessionid=696890CAB45EBF2E3C87D2130F1D510F;jsessionid=C6EEB24438E91236A278BAA17D0F98DE;jsessionid=4E424E1535B964284C2AF9C387DA16C3;jsessionid=488CBD111883FD29309C48C3F67E3ED2;jsessionid=6BA0878CC96DB080B124A8A3304A3FB1;jsessionid=21B9763974C3FDC50FB2633B16499D1E;jsessionid=FA881359FEC92A550637831A469F2212;jsessionid=437262EB9AC2F39707B37A3517899648